AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00454246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in a 1-mL prefilled syringe containing 0.3 mL or 0.6 mL solution. The methoxy polyethylene glycol-epoetin beta injectable solution was formulated in sodium phosphate, sodium sulfate, mannitol, methionine and poloxamer 188, pH 6.2 and did not contain any preservative. Participants received methoxy polyethylene glycol-epoetin beta subcutaneous once a month.
Study NCT00454246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa
Description: Standard of care as prescribed, per individual participant, subcutaneous once per week. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.
Study NCT00454246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: Standard of care as prescribed, per individual participant, darbepoetin alfa subcutaneous once every two weeks. Subcutaneous injections were to be administered in the same part of the body (ie, thigh,abdomen or arm) throughout the study.
Study NCT00433589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anthracycline-based
Study NCT00433589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anthracycline-based
Study NCT00433589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and capecitabine
Study NCT00433589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and capecitabine
Study NCT00433589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Study NCT02208180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Return of genomic results on cardiovascular disease risk
Description: Experimental group: Participants will receive genomic cardiovascular disease risk information.~Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study.
Study NCT02208180 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Return of genomic results on cardiovascular disease risk
Description: Experimental group: Participants will receive genomic cardiovascular disease risk information.~Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study.
Study NCT01303666 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular CSI
Description: After full aseptic preparation, 40 mg triamcinolone acetonide and 2 ml 1% lignocaine were injected into the joint cavity using the medial patello-femoral approach via a 21-gauge needle.
Study NCT01303666 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TI of the knee
Description: This was done as a day case procedure under local anaesthetic. The medial patello-femoral approach was used. After full aseptic preparation, the skin and soft tissues were infiltrated with 5e10 ml of 1% lignocaine. The joint was then instilled with a further 10 ml of 1% lignocaine.~After an initial puncture using a scalpel, a 3.2 mm diameter wrist arthroscope was advanced into the joint cavity. Up to 1 l of 0.9% normal saline was then irrigated through the joint: saline was run into the joint until fully distended and then allowed to flow out of the joint in a cyclical method until the aspirated fluid runs clear for at least three successive cycles.
Study NCT02246517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N2O
Study NCT00433589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Study NCT00433589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT02246517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Study NCT03317977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach for Control
Description: In Phase 1 (weeks 1-4), the CHW conducts an initial intake and then completes a comprehensive functional analysis (FA) of behavior to determine the causes of poor asthma management for each youth regarding asthma management. In Phase 2 (weeks 5-20) is a treatment phase and consists of a combination of mandatory cognitive-behavioral skills training (CBST) modules (received by all families) and flexible CBST modules chosen and individualized based on the results of the Phase 1 FA. This includes but not limited to In-vivo Asthma Skills Training, Improving Family Communication and Behavioral Contracting. Phase 3 (weeks 21-24) involves termination planning and relapse prevention
Study NCT03317977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MATCH
Description: Managing Asthma Through Case Management in Home (MATCH) is the current intervention provided by WCHAP to youth with poorly controlled asthma and their families.
Study NCT03199625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Study NCT03199625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Study NCT03199625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI antidepressants
Study NCT00278434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronate
Study NCT00278434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Study NCT00333463 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intervention
Description: The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
Study NCT00943540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir QD
Description: Raltegravir 800mg QD
Study NCT00943540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir
Description: atazanavir
Study NCT00943540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine (or emtricitabine)
Description: lamivudine (or emtricitabine)
Study NCT02498444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treprostinil
Description: Administration of drug (treprostinil) vs placebo (saline) in the post-operative period
Study NCT02498444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: Administration of drug (treprostinil) vs placebo (saline) in the post-operative period
Study NCT00746564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SJM Confirm
Description: All patients in this study will receive the SJM Confirm device.
Study NCT01997788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The intrathecal morphine injection
Description: A single injection of morphine intrathecally
Study NCT01997788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The intravenous patient-controlled analgesia
Description: The intravenous injection of morphine using the patient-controlled analgesia machine
Study NCT01997788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The intravenous patient-controlled analgesia
Description: The intravenous injection of morphine using the patient-controlled analgesia machine
Study NCT01997788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demerol on demand
Description: Demerol 25 mg intravenously when pain scores more than 5.
Study NCT01997788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Demerol on demand
Description: Demerol 25 mg intravenously when pain scores more than 5.
Study NCT00546377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00546377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Study NCT00546377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00546377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00546377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT01367327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loaded sit-to-stand exercise
Description: Loaded sit-to-stand exercise at home, 3 times a week for 6 weeks
Study NCT01367327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Loaded sit-to-stand exercise
Description: Loaded sit-to-stand exercise at home, 3 times a week for 6 weeks
Study NCT01367327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Synchronized music
Description: Synchronized music for loaded sit-to-stand exercise to guide movement
Study NCT04637204 — intervention group
Intervention type: DRUG
Intervention: Cabozantinib
Description: oral therapy
Study NCT04637204 — intervention group
Intervention type: DRUG
Intervention: Axitinib
Description: oral therapy
Study NCT02742168 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-3PRGD2
Description: Diagnostic group：For patients in suspicion of breast cancer, single intravenous bolus injection of nearly 0.3 mCi/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and lesions SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.~Efficacy evaluation group：patients firstly diagnose with malignant lesions ,and prepare to chemotherapy(including neoadjuvant chemotherapy) or radiotherapy.the same dose of 99mTc-3PRGD2 will be intravenously injected into the patients before treatment ,the second period,the sixth period( almost three months after the initial treatment)，whole-body planar and lesions SPECT/CT to assess the value of 99mTc-3PRGD2 in evaluation of cancers.
Study NCT02457039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dense cranial electroacupuncture stimulation
Description: DCEAS is a is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz).
Study NCT02457039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Body acupuncture
Description: Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Wai-Guan (TE5), Zhong-Wan (CV12), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation. No electrical stimulation is delivered.
Study NCT00546377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Study NCT00546377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentostatin
Study NCT00546377 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Study NCT00546377 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene rearrangement analysis
Study NCT02457039 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Least acupuncture stimulation
Description: The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (GB17), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (GB17) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
Study NCT02457039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytoxan-containing chemotherapy regimens
Description: Each subject shall receive oral administration or venous injection or both with adjuvant or neoadujuvant chemotherapy regimens, as decided by clinical oncologist.~In clinical practice, the most commonly used Cytoxan-containing regimens include but are not limit to:~AC (x4) \[Adriamycin + Cytoxan\], TC (x4) \[Taxotere + Cytoxan\], AC-P (4+4) \[Adriamycin + Cytoxan + Paclitaxel\], TAC (x6) \[Taxotere + Adriamycin + Cytoxan\], or AC-PH (4+4) \[Adriamycin + Cytoxan + Paclitaxel + Herceptin\].
Study NCT02457039 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cytoxan-containing chemotherapy regimens
Description: Each subject shall receive oral administration or venous injection or both with adjuvant or neoadujuvant chemotherapy regimens, as decided by clinical oncologist.~In clinical practice, the most commonly used Cytoxan-containing regimens include but are not limit to:~AC (x4) \[Adriamycin + Cytoxan\], TC (x4) \[Taxotere + Cytoxan\], AC-P (4+4) \[Adriamycin + Cytoxan + Paclitaxel\], TAC (x6) \[Taxotere + Adriamycin + Cytoxan\], or AC-PH (4+4) \[Adriamycin + Cytoxan + Paclitaxel + Herceptin\].
Study NCT03006523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemination
Description: IUI will be performed with a Wallace® insemination 2 Catheter (Cooper Surgical, Trumbull, CT, USA) depositing 0.2 or 0.5 ml of the sperm sample at the uterine fundus. All IUIs will be performed between 12 p.m. and 4 p.m. After the procedure, 10 min of bed rest will be prescribed. Inseminations will be performed every day of the week, including weekends.
Study NCT03006523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination
Description: IUI will be performed with a Wallace® insemination 2 Catheter (Cooper Surgical, Trumbull, CT, USA) depositing 0.2 or 0.5 ml of the sperm sample at the uterine fundus. All IUIs will be performed between 12 p.m. and 4 p.m. After the procedure, 10 min of bed rest will be prescribed. Inseminations will be performed every day of the week, including weekends.
Study NCT00126555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Undergo surgery
Study NCT02372396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Meditation (CM)
Description: Compassion meditation is a meditative practice focused on the wish that others and the self may be free of suffering. Because this particular form of meditation has been shown to elicit positive emotion and feelings of connection with other people, it is uniquely well suited to addressing PTSD, which is characterized by strong negative affect, deficits in positive emotion and social connectedness.
Study NCT02372396 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: Relaxation Training is selected as the control condition because it is a good match for nonspecific aspects of the meditative practice (e.g., attention, support, contact with a mental health provider) and it is structurally similar to meditation (e.g., restful, in session and at home exercises).
Study NCT00456638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depodur
Description: Depodur vs. traditional management
Study NCT00456638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depodur
Description: Depodur vs. traditional management
Study NCT04459026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combination
Description: instillation and infiltration of ropivacaine
Study NCT00126555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04459026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: infiltration
Description: local infiltration ropivacaine
Study NCT04459026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: instillation
Description: intraperitoneal ropivacaine instillation
Study NCT03543826 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Protocol for rocuronium neuromuscular block
Description: The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
Study NCT00536003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone
Description: vaginal capsules containing 200 mg of natural progesterone, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
Study NCT00536003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
Study NCT03424824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1.3656 low dose
Description: Tablet, once daily oral administration at the low dose
Study NCT03424824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1.3656 intermediate dose
Description: Tablet, once daily oral administration at the intermediate dose
Study NCT03424824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, once daily oral administration
Study NCT03424824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1.3656 high dose
Description: Tablet, once daily oral administration at the high dose
Study NCT01716312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omalizumab
Description: For each subject, treatment with omalizumab will start with a loading dose of 600 mg followed by a maintenance dose of 300 mg every 4 weeks. The study drug will be administered as a subcutaneous injection. On Week 0 and Week 16 the medication or placebo will be administered to subjects via 4 subcutaneous injections; the remaining weeks 2 injections will be administered.Subjects will be given written directions on dealing with adverse reactions. They will also receive an Epi-Pen before discharge and instructions on how to use it.
Study NCT01716312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: For each subject, treatment with omalizumab will start with a loading dose of 600 mg followed by a maintenance dose of 300 mg every 4 weeks. The study drug will be administered as a subcutaneous injection. On Week 0 and Week 16 the medication or placebo will be administered to subjects via 4 subcutaneous injections; the remaining weeks 2 injections will be administered.Subjects will be given written directions on dealing with adverse reactions. They will also receive an Epi-Pen before discharge and instructions on how to use it.
Study NCT02073396 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Patients will undergo the tests of thrombosis, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study.
Study NCT01306773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H1N1 convalescent plasma and oseltamivir
Description: Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma containing >= 1:160 of neutralizing antibody to Pandemic influenza A H1N1
Study NCT01306773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Oseltamivir alone
Description: Oral Oseltamivir 75mg bid during ICU hospitalization
Study NCT02352311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKF-313
Description: Combination of dutasteride 0.5 mg and tadalafil 5 mg
Study NCT02352311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVODART
Description: Dutasteride 0.5 mg
Study NCT02352311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIALIS
Description: Tadalafil 5 mg
Study NCT04509947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S will be administered as IM injection at 2-dose (high and low) levels.
Study NCT04509947 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as IM injection.
Study NCT00527696 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal obturator tape
Study NCT03321188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC with cisplatin
Study NCT03321188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Adjuvant IV chemotherapy
Study NCT03321188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Adjuvant IV chemotherapy
Study NCT01136733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: taken orally, once a day
Study NCT01136733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: taken orally, once a day
Study NCT01136733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: taken orally, once a day
Study NCT02884921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol
Study NCT02884921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo